Product Name: HIPK1 (349-355) pY352
Product Number: PE-04AKK95
Size: 200 µg      Price:47.00
1 mg      $US94.00
5 mg      206.00
Peptide Name: HIPK1 (349-355) pY352

Product Use: Services as a blocking peptide for use with the HIPK1-pY352 rabbit polyclonal antibody (Cat. No.: AB-PK654) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. This is the major in vivo phosphorylation site in HIPK1. Y352 phosphorylation is predicted to be stimulatory for phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: CST-pY-LQS

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1022 Da

Peptide Purity Percent after Synthesis and Purification: >90

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: HIPK1 - pY352 phosphosite-specific antibody (Cat. No.: AB-PK654)

Scientific Background: HIPK1 (HIK1) is a protein-serine/threonine kinase of the CMGC group and DYRK family. It functions in transcription regulation as well as tumour necrosis factor (TNF)-mediated apoptosis. HIPK1 is also known to act as a co-repressor for homeodomain transcription factors. In the absence of TNF, HIPK1 prevents MAP3K5-JNK activation. When present, TNF induces nuclear translocation of HIPK1, thus removing it from the cytoplasm, resulting in the activation of MAP3K5-JNK signalling by de-repression. In addition, through the direct phosphorylation of p53 at the S15 residue, HIPK1 activates p53 leading to increased p21 protein levels, which subsequently inhibits cell proliferation. HIPK1 may be a tumour suppressor protein (TSP). Over-expression of HIPK1 has been observed in colorectal cancer specimens, with highest levels at the beginning of tumourigenesis followed by a progressive reduction over time as the cancer develops, indicating a role for the HIPK1 protein in the early events of tumourigenesis. in addition, these specimens also displayed native p53 and normal levels of p21, indicating that the HIPK1 protein functions as a tumour suppressor and that a loss-of-function in the protein is associated with tumourigenesis.